Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
Daiichi Sankyo rolled out its oncolytic virus Delytact (G47∆; teserpaturev) in Japan on November 1. It will initially supply the therapy to medical institutions where its clinical trials were conducted but hopes to set up a stable supply system as…
To read the full story
Related Article
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
BUSINESS
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…